NanoEntek Past Earnings Performance
Past criteria checks 0/6
NanoEntek's earnings have been declining at an average annual rate of -19.2%, while the Life Sciences industry saw earnings growing at 23.4% annually. Revenues have been growing at an average rate of 5% per year.
Key information
-19.2%
Earnings growth rate
-19.6%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 5.0% |
| Return on equity | -6.9% |
| Net Margin | -13.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
NanoEntek, Inc.'s (KOSDAQ:039860) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Mar 21
Should Weakness in NanoenTek, Inc.'s (KOSDAQ:039860) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 14If You Had Bought NanoEnTek (KOSDAQ:039860) Shares A Year Ago You'd Have Earned 48% Returns
Jan 26Calculating The Intrinsic Value Of NanoEnTek, Inc. (KOSDAQ:039860)
Jan 04NanoEnTek Inc.'s (KOSDAQ:039860) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Dec 14Does NanoEnTek's (KOSDAQ:039860) Statutory Profit Adequately Reflect Its Underlying Profit?
Nov 23Revenue & Expenses BreakdownBeta
How NanoEntek makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 26,837 | -3,678 | 9,794 | 3,689 |
| 30 Sep 23 | 26,656 | -5,043 | 9,867 | 3,550 |
| 30 Jun 23 | 29,016 | -1,199 | 10,038 | 3,550 |
| 31 Mar 23 | 31,574 | 2,505 | 8,927 | 3,550 |
| 31 Dec 22 | 35,201 | 4,665 | 8,068 | 3,550 |
| 30 Sep 22 | 37,711 | 7,505 | 8,387 | 2,968 |
| 30 Jun 22 | 36,035 | 5,961 | 7,914 | 2,968 |
| 31 Mar 22 | 34,502 | 6,028 | 7,552 | 2,968 |
| 31 Dec 21 | 35,784 | 7,321 | 8,021 | 2,968 |
| 30 Sep 21 | 36,107 | 6,944 | 8,979 | 2,455 |
| 30 Jun 21 | 35,076 | 6,235 | 8,244 | 2,455 |
| 31 Mar 21 | 34,513 | 4,463 | 7,871 | 2,455 |
| 31 Dec 20 | 29,443 | 2,737 | 7,147 | 2,455 |
| 30 Sep 20 | 26,319 | 3,887 | 9,155 | 386 |
| 30 Jun 20 | 26,987 | 5,565 | 8,486 | 825 |
| 31 Mar 20 | 28,102 | 7,182 | 7,537 | 1,182 |
| 31 Dec 19 | 26,256 | 5,750 | 6,744 | 1,519 |
| 30 Sep 19 | 25,388 | 4,407 | 6,372 | 1,452 |
| 30 Jun 19 | 24,895 | 3,500 | 6,151 | 1,276 |
| 31 Mar 19 | 23,851 | 2,843 | 5,937 | 1,222 |
| 31 Dec 18 | 25,797 | 3,308 | 5,674 | 1,241 |
| 30 Sep 18 | 25,754 | 718 | 5,337 | 1,340 |
| 30 Jun 18 | 25,474 | 138 | 5,628 | 1,463 |
| 31 Mar 18 | 24,895 | -658 | 5,877 | 1,496 |
| 31 Dec 17 | 23,810 | -2,072 | 5,565 | 1,376 |
| 30 Sep 17 | 23,080 | -7,385 | 7,756 | 1,591 |
| 30 Jun 17 | 22,454 | -9,621 | 8,015 | 1,712 |
| 31 Mar 17 | 22,289 | -12,957 | 9,410 | 1,893 |
| 31 Dec 16 | 22,206 | -14,799 | 10,628 | 2,111 |
| 30 Sep 16 | 24,877 | -11,146 | 10,788 | 2,020 |
| 30 Jun 16 | 24,730 | -10,679 | 11,214 | 1,734 |
| 31 Mar 16 | 25,706 | -8,777 | 10,108 | 1,535 |
| 31 Dec 15 | 24,839 | -7,282 | 10,019 | 1,332 |
| 30 Sep 15 | 23,548 | -3,145 | 7,902 | 980 |
| 30 Jun 15 | 22,069 | -2,736 | 7,011 | 942 |
| 31 Mar 15 | 19,664 | -2,745 | 6,633 | 859 |
| 31 Dec 14 | 19,499 | -2,464 | 5,874 | 740 |
| 30 Sep 14 | 19,097 | -2,117 | 5,291 | 495 |
| 30 Jun 14 | 19,529 | -1,752 | 4,697 | 388 |
| 31 Mar 14 | 19,253 | -1,035 | 4,471 | 329 |
| 31 Dec 13 | 19,084 | -1,237 | 4,278 | 438 |
| 30 Sep 13 | 16,676 | -4,232 | 4,915 | 853 |
| 30 Jun 13 | 15,123 | -5,305 | 5,498 | 882 |
Quality Earnings: A039860 is currently unprofitable.
Growing Profit Margin: A039860 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A039860 is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Accelerating Growth: Unable to compare A039860's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A039860 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.1%).
Return on Equity
High ROE: A039860 has a negative Return on Equity (-6.86%), as it is currently unprofitable.